[et_pb_section fb_built=”1″ admin_label=”! !! NE PAS MODIFIER ! !! ” _builder_version=”4.19.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_row admin_label=”!!! PLEASE DO NOT EDIT !!! ” _builder_version=”4.19.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.19.5″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”TO BE EDITED – SUMMARY” _builder_version=”4.21.0″ _module_preset=”default” custom_padding=”||20px||false|false” global_colors_info=”{}”]<\/p>\n
The government and the pharmaceutical industry have strengthened their partnership through the Comit\u00e9 \u00e9conomique des produits de sant\u00e9 and Les entreprises du m\u00e9dicament to combine competitiveness, access to innovation and cost containment as part of the Social Security Financing Bill 2025.<\/strong><\/p>\n [\/et_pb_text][et_pb_text admin_label=”TO BE EDITED – TEXT OF THE NEWS – BLOCK 1 ” _builder_version=”4.21.0″ _module_preset=”default” custom_padding=”||1em||false|false” global_colors_info=”{}”]<\/p>\n The French government and the pharmaceutical industry, represented by the Comit\u00e9 \u00e9conomique des produits de sant\u00e9 (Ceps) and Les entreprises du m\u00e9dicament (Leem), have recently embarked on a new contractual dynamic. The aim of this partnership is to reconcile industrial competitiveness and control of public healthcare expenditure, while guaranteeing access to therapeutic innovations and security of supply. It is part of the Social Security Financing Bill (PLFSS) for 2025, in response to an alert concerning a potential \u20ac1.2 billion overspend on drugs. <\/p>\n [\/et_pb_text][et_pb_text admin_label=”TO BE EDITED – TEXT OF THE NEWS – BLOCK 2 ” _builder_version=”4.21.0″ _module_preset=”default” custom_padding=”||1em||false|false” global_colors_info=”{}”]<\/p>\n The agreement includes several key measures, such as limiting the safeguard clause to \u20ac1.6 billion, which caps pharmaceutical company contributions to the Social Security budget. In addition, 600 M\u20ac of savings will be sought through the proper use of medicines, notably via “delisting” (access without prescription) of certain treatments without affecting their reimbursement. This strategy aims to rationalize prescriptions while maintaining access to care for patients. <\/p>\n [\/et_pb_text][et_pb_text admin_label=”TO BE EDITED – TEXT OF THE NEWS – BLOCK 3″ _builder_version=”4.21.0″ _module_preset=”default” custom_padding=”||1.5em||false|false” global_colors_info=”{}”]<\/p>\n Finally, joint management tools will be introduced to secure national and European production of strategic medicines. This industrial initiative is part of a strategy to promote healthcare sovereignty, reducing France’s dependence on imports from outside the European Union and simplifying access to medical innovations for patients. This partnership bears witness to a shared determination to guarantee both the sustainability of the healthcare system and the development of a competitive and resilient pharmaceutical industry. <\/p>\n [\/et_pb_text][et_pb_text admin_label=”TO BE EDITED – TEXT OF THE NEWS – BLOCK 4″ _builder_version=”4.21.0″ _module_preset=”default” custom_padding=”||1em||false|false” global_colors_info=”{}”]<\/p>\n Find out more<\/strong><\/p>\n The Government and the pharmaceutical industry commit to a new contractual dynamic<\/a>, Press release – Ministry of the Economy, Finance and Industry, November 21, 2024.<\/p>\n